FDA Accepts Supplement Application for ONTRUZANT (Trastuzumab-DTTB)
The FDA has accepted the supplemental application for ONTRUZANT, a biosimilar to trastuzumab.
Asset / Drug
Drug and asset intelligence for ONTRUZANT with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.